A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

Exclusion Criteria

• •Patients with prior head and neck radiation therapy where there is \>30% overlap with the current head and neck radiation fields. Exceptions can be made if determined by the PI/Co-PI that the patient can proceed with protocol activities
• •Patients whose tumors are borderline T4 based on anterior tumor extension to the extrinsic muscles of the tongue
• •Patients with simultaneous primary cancers outside of the oropharynx
• •o Note: Exceptions can be made for patients with simultaneous primaries outside the oropharynx if determined by the PI/Co-PI the patient can proceed with protocol activities
• •Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years to be 90% or greater
• •o Note: Exceptions can be made for patients with prior malignancies outside the oropharynx if determined by the PI/Co-PI the patient can proceed with protocol activities.
• •Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
• •No particle therapy
• •Patients who are deemed non-compliant to all the protocol related activities
• •Contraindications to receive either cisplatin or the combination of carboplatin/5-fluorouracil at the prescribed doses.
• •Severe, active co-morbidity defined as follows:
• •* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
• •* Transmural myocardial infarction within the last 6 months
• •* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• •* Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
• •* Hepatic Insufficiency resulting in clinical jaundice and/or coagulation defects